HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

IgG4-related sclerosing cholangitis — Clinical Guidelines

Overview

IgG4-related sclerosing cholangitis is a fibroinflammatory condition characterized by elevated IgG4-positive plasma cells, storiform fibrosis, and organ-specific manifestations, often involving the biliary tract alongside other organs such as the pancreas, salivary glands, and lymph nodes 1 9.

Diagnosis

Histological Diagnosis: Essential, featuring IgG4-positive plasma cells (IgG4/IgG ratio >40%) and storiform fibrosis 1.

Serological Markers: Elevated serum IgG and IgG4 levels 1.

Imaging: Utilizes CT, MRI, and FDG-PET/CT for staging and monitoring treatment response 10.

Classification Criteria: Use 2019 ACR/EULAR criteria, validated across diverse populations including Latin America and China 2 3.

Exclusion Criteria: Rule out other mimicking conditions through clinical judgment and comprehensive evaluation 4.

Organ Correlation: Consider involvement of multiple organs, particularly autoimmune pancreatitis, sclerosing cholangitis, and sialadenitis 9.

Management

First-Line Treatment: Glucocorticoids (e.g., prednisone) are typically initiated 1 8.

Adjunctive Therapy: Consider immunosuppressive agents like rituximab for refractory cases 1 8.

Monitoring: Regular imaging (FDG-PET/CT) and serological monitoring to assess response and disease activity 10.

Dose Adjustment: Tailor glucocorticoid dosing based on clinical response and side effects 1.

Special Populations

Pregnancy: Limited data; individualized management with close monitoring advised [Expert opinion: No specific evidence provided in abstracts].

Elderly: Consider comorbidities and potential drug interactions when selecting immunosuppressive therapies [Expert opinion: No specific evidence provided in abstracts].

Comorbidities: Manage concurrent autoimmune conditions carefully, adjusting treatments to avoid exacerbations [Expert opinion: No specific evidence provided in abstracts].

Key Recommendations

Utilize 2019 ACR/EULAR Classification Criteria for Diagnosis: Essential for accurate diagnosis across diverse populations (Evidence: Strong 2 3).

Initiate Glucocorticoids as First-Line Therapy: Effective in managing IgG4-related sclerosing cholangitis (Evidence: Moderate 1 8).

Employ FDG-PET/CT for Monitoring Disease Activity and Treatment Response: Valuable for staging and follow-up (Evidence: Moderate 10).

References

1 Chen LYC. IgG4-related disease for the hematologist. Hematology. American Society of Hematology. Education Program 2024. link 2 Martín-Nares E, Hernández-Molina G, Baenas DF, Delgado de la Mora J, Caeiro F, Wurmann Kiblisky P et al.. Performance of the 2019 American College of Rheumatology/European League Against Rheumatism Classification Criteria for IgG4-Related Disease in a Latin American Cohort. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 2024. link 3 Liu Z, Nie Y, Peng Y, Lu H, Zhang P, Li J et al.. The external validation of the 2019 ACR/EULAR classification criteria for IgG4-related disease in a large cohort from China. Seminars in arthritis and rheumatism 2023. link 4 Kogami M, Abe Y, Ando T, Makiyama A, Yamaji K, Tamura N. Performance of classification and diagnostic criteria for IgG4-related disease and comparison of patients with and without IgG4-related disease. Scientific reports 2023. link 5 Chen YJ, Hsu CY, Lin CH. Chronic Leg Ulcer Associated with Cutaneous IgG4-Related Disease. The international journal of lower extremity wounds 2023. link 6 Ren H, Mori N, Sato S, Mugikura S, Masamune A, Takase K. American College of Rheumatology and the European League Against Rheumatism classification criteria for IgG4-related disease: an update for radiologists. Japanese journal of radiology 2022. link 7 Wallace ZS, Naden RP, Chari S, Choi H, Della-Torre E, Dicaire JF et al.. The 2019 American College of Rheumatology/European League Against Rheumatism Classification Criteria for IgG4-Related Disease. Arthritis & rheumatology (Hoboken, N.J.) 2020. link 8 Sebastian A, Sebastian M, Misterska-Skóra M, Donizy P, Hałoń A, Chlebicki A et al.. The variety of clinical presentations in IgG4-related disease in Rheumatology. Rheumatology international 2018. link 9 Koizumi S, Kamisawa T, Kuruma S, Tabata T, Chiba K, Iwasaki S et al.. Organ Correlation in IgG4-Related Diseases. Journal of Korean medical science 2015. link 10 Ebbo M, Grados A, Guedj E, Gobert D, Colavolpe C, Zaidan M et al.. Usefulness of 2-[18F]-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography for staging and evaluation of treatment response in IgG4-related disease: a retrospective multicenter study. Arthritis care & research 2014. link 11 Stone JH. IgG4: a tantalizing link between causes of membranous glomerulonephritis and systemic disease. Kidney international 2013. link 12 Yamamoto M, Takahashi H, Ohara M, Suzuki C, Naishiro Y, Yamamoto H et al.. A new conceptualization for Mikulicz's disease as an IgG4-related plasmacytic disease. Modern rheumatology 2006. link

IgG4-related sclerosing cholangitis